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Abstract

PREVALENCE OF ANTI-DIABETIC AND ANTILIPIDEMIC MEDICATIONS IN
CHILDREN AND ADOLESCENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS IN A
VIRGINIA MEDICAID POPULATION
by
Della Varghese, PharmD

A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Pharmaceutical Sciences at Virginia Commonwealth University

Virginia Commonwealth University, 2013

Major Director: Cynthia K Kirkwood, Pharm.D., BCPP
Professor and Vice Chair for Education
Department of Pharmacotherapy and Outcomes Science

Objective: To determine if the prevalence of anti-diabetic and antilipidemic medication use
among children treated with atypical antipsychotics is higher than those not treated with
antipsychotics.
Methods: Virginia Medicaid beneficiaries (2-17 years) continuously enrolled from August 1,
2010 to July 31, 2011 with at least two prescription claims for atypical antipsychotics were the
exposed group. All other subjects during the study period were the non-exposed group.
Prevalence of anti-diabetic and antilipidemic medication use in both groups were computed and
compared using Chi-square test (α=0.05).

ix

Results: A total of 299,593 and 4,922 subjects were identified as the non-exposed and exposed
groups, respectively. Prevalence of anti-diabetic medication use was 0.32% in the unexposed and
1.40% in the exposed group (p<0.0001). Prevalence of antilipidemic medication use was 0.09%
in the unexposed and 0.35% in the exposed group (p<0.0001).
Conclusion: Prevalence of anti-diabetic and antilipidemic medication use in the exposed group
was significantly higher.

CHAPTER 1: Introduction

A. Background
One in four adults experience a psychiatric disorder in any given year.1,2 According to the
National Survey on Drug Use and Health (NSDUH), 13.4% of adults in the United States (US)
received treatment for mental illness in 2008.3 Mental health disorders have also been an issue
among children and adolescents. One in ten children have a serious emotional disorder.1,4
Antipsychotics have become the mainstay of treatment for a number of psychiatric disorders
(e.g., psychosis, mood disorders, tic disorder, disruptive behavior disorder).5
A national survey conducted on youth in 2002 by Olfson et al. showed that there was a 6-fold
increase in the number of office visits which resulted in a prescription for an antipsychotic
medication between 1993 and 2002.5 Another survey conducted by Olfson et al. from 2005 to
2009 showed that there was a higher number of male patients among children and adolescents
with office visits that resulted in the prescription of an antipsychotic agent.6 A larger percentage
of the children had antipsychotic visits for disruptive behaviors disorders in comparison with
schizophrenia and bipolar mania. Only a small proportion of the diagnoses for children who
received an antipsychotic prescription were for a Food and Drug Administration (FDA) approved
indication. The most common off-label indication treated was attention-deficit/hyperactivity
disorder. Risperidone was the most commonly prescribed antipsychotic agent.6
Use of second generation antipsychotics, or atypical antipsychotics, has increased because of the
propensity to cause less adverse extrapyramidal symptoms (EPS) (i.e., dystonia, akathisia,
pseudoparkinsonism, tardive dyskinesia) compared with the typical antipsychotics.7 Typical
antipsychotics have been replaced by atypical antipsychotics, for the treatment of schizophrenia.
1

Studies have shown that atypical antipsychotics are at least as effective as the typical
medications in the treatment of psychiatric disorders such as schizophrenia and there has been a
rapid rise in the use of atypical antipsychotics.8-13 According to Olfson et al. of the total number
of antipsychotics used by a pediatric population, about 92% was classified as atypical
antipsychotics.5
With increased use of atypical antipsychotics among children and adolescents, the FDA has
approved some of these atypical agents for use in the pediatric population. As of 2011,
aripiprazole, olanzapine, quetiapine, and risperidone have been labeled for use in children with
bipolar mania (age 10-17 years; olanzapine: 13-17 years) and schizophrenia (13-17 years of
age). Paliperidone is indicated for adolescents with schizophrenia (12-17 years). Aripiprazole
and risperidone also have an indication for irritability/aggression associated with autism (6-17
years of age).14 Risperidone and aripiprazole were the first atypical antipsychotics to receive a
pediatric indication in 2007.
Recently, there has been increased concern about the metabolic adverse effects profile of the
atypical agents in both adults and children. Evidence from adult studies suggest that atypical
antipsychotics are linked with metabolic disturbances; most commonly weight gain,
hyperglycemia, diabetes, and hyperlipidemia.15 Newer studies indicate that these effects are also
seen among children and adolescents.16 A study by Correll et al. showed that atypical
antipsychotics were associated with weight gain, obesity, metabolic syndrome, dyslipidemia,
glucose abnormalities, and decreased insulin sensitivity in children ages 4 through 19
years. Metabolic syndrome in children and adolescents is characterized by 3 or more of the
following criteria: a blood pressure greater than 90th percentile, obesity with Body Mass Index
(BMI) greater than or equal to the 95th percentile, triglyceride levels greater than 110 mg/dL,
2

fasting glucose greater than or equal to 100 mg/dL, and a high density lipoprotein (HDL) less
than 40 mg/dL.16
Correll et al. reported that in children, atypical antipsychotics have the propensity to cause rapid
weight gain and increases in BMI (>95th percentile) leading to complications such as obesity
(>7% increase in weight), glucose abnormalities (i.e., hyperglycemia), dyslipidemia, and
metabolic syndrome.16 This is of concern as studies have shown that an increase in weight during
childhood is a determinant of cardiovascular risk.17 Weight has a direct correlation with
cardiovascular disease. Childhood BMI, weight, and height were significantly correlated with
increase in weight, BMI, height, insulin and lipid levels, and systolic blood pressure during
adulthood.17 Other studies showed that higher BMI during childhood was associated with
increased fatal heart diseases as adults.17,18 Childhood obesity is also a predictor of adulthood
obesity and diabetes,19 which are both risk factors for the development of type 2 diabetes mellitus
and hyperlipidemia during childhood.15 However the prevalence of anti-diabetic and
antilipidemic medication use among children and adolescents using atypical antipsychotics has
not been characterized.
B. Objective and Specific Aims
The objective of this study was to determine if the prevalence of anti-diabetic and antilipidemic
medication use among children and adolescents treated with atypical antipsychotics is higher
than the prevalence among children and adolescents not treated with atypical antipsychotics.
Another goal of the study was to determine the odds of receiving an anti-diabetic or
antilipidemic medication based on individual atypical antipsychotic therapy.
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This study had the following specific aims:
Specific Aim IA:
To determine and compare the prevalence of anti-diabetic medication use in children and
adolescents treated with atypical antipsychotics to those not treated with atypical antipsychotics.
Specific Aim IB:
To determine and compare the prevalence of antilipidemic medication use in children and
adolescents treated with atypical antipsychotics to those not treated with atypical antipsychotics.
Specific Aim IIA:
To examine the relationship between the use of individual atypical antipsychotic agents and use
of anti-diabetic medication in children and adolescents.
Specific Aim IIB:
To examine the relationship between the use of individual atypical antipsychotic agents and use
of antilipidemic medication in children and adolescents.

4

C. Significance
The metabolic adverse effects of atypical antipsychotics have become problematic among
children and adolescents. Increased weight gain and other metabolic effects are usually
precursors to the development of diabetes and hyperlipidemia. There are studies in the adult
population that observed the development of type 2 diabetes or hyperlipidemia after initiation of
antipsychotic treatment.12, 13 There is a similar study by Andrade et al. that evaluated the risk of
development of type 2 diabetes mellitus in children and adolescents.20 Our trial is innovative
because no study to date has directly investigated the prevalence of anti-diabetic and
antilipidemic medication use in children and adolescents less than 17 years of age treated with
atypical antipsychotic agents. There are also no published data on the association between each
atypical agent and the use of anti-diabetic or antilipidemic medications. The main objectives of
our study were to determine the prevalence of anti-diabetic and antilipidemic medication use
among children and adolescents receiving atypical antipsychotics, and to evaluate whether the
prevalence of anti-diabetic and lipid lowering medication use differs among the atypical
antipsychotic agents. Documenting the odds of receiving an anti-diabetic or antilipidemic
medication based on individual atypical agent can help clinicians make informed decisions
regarding drug selection among the various atypical antipsychotics. It will help clinicians decide
which atypical agents have the least amount of risk, and should be considered for children and
adolescents, and which of these agents should be avoided if possible.

5

Chapter 2: Literature Review
A. Antipsychotic Medication Prescribing Trend
Studies that involved children enrolled in Medicaid programs and Health Maintenance
organizations (HMO) have shown that there is a significant increase in the use of
antipsychotics.21-23 The study by Patel et al. showed that antipsychotic use was prominent among
10- to 19-year-olds but the greatest increase in use was seen among 5- to 9-year-olds.23 The study
by Cooper et al. reported that during 1995 to 2002, there were 5,762,193 outpatients visits,
during which an antipsychotic was prescribed, by children in the United States less than 18 years
of age. Two-thirds of these children were male and the mean age was 12.9 years. The frequency
of antipsychotic prescriptions for children had increased from 8.6 per 1000 children in 19951996 to 39.4 per 1000 children in 2001-2002.21 A very recent study by Zito et al. showed that the
overall prevalence of antipsychotic use increased from 1.2% in 1997 to 3.2% in 2006.24
B. Metabolic Adverse Effects of Atypical Antipsychotics
As stated in the previous chapter, the majority of the antipsychotic prescriptions for children and
adolescents are for atypical antipsychotics since these agents are associated with lower risk of
EPS. Although atypical agents have lower propensity to cause EPS, there is an increasing
concern about whether these agents induce serous metabolic adverse effects (i.e., weight gain,
hyperglycemia and hyperlipidemia). A review by Newcomer showed that atypical antipsychotics
are associated with increased weight gain, decreased insulin sensitivity, and changes in lipid
profiles thus increasing the risk of patients to develop type 2 diabetes mellitus, hyperlipidemia,
and metabolic syndrome.25 Metabolic syndrome is common in obese patients and predisposes
children to atherosclerotic cardiovascular disease.26
6

Weight: It has been shown that use of atypical antipsychotics has been associated with increased
weight gain. Olanzapine and risperidone were commonly studied antipsychotics and though both
cause increased weight gain, olanzapine seems to be associated with significantly greater weight
gain. One of the largest cohort studies conducted in a pediatric population of first-time atypical
antipsychotic users showed that olanzapine caused a mean increase of 8.5 kg (95% confidence
interval [CI] = 7.4 - 9.7 kg) after a median of 10.8 weeks. The study looked at a wide array of
antipsychotics and all caused varying degrees of weight gain in order of olanzapine> quetiapine>
risperidone> aripiprazole. They also had a comparison untreated group which had minimal
weight change of 0.2 kg (95% CI = -1.0 - 1.4 kg) within the same time frame.16
Another study showed that during the course of treatment (27 days), 7 new cases or 28% within
the olanzapine group and 4 new cases or 17% within the risperidone group were overweight or at
risk of being overweight with a BMI> 85%.27 Another longitudinal study showed that even
though there was a significant increase in the BMI z score in the olanzapine and risperidone
groups (p<0.05), there was no significant weight gain in the quetiapine group. At the end of the
6-month, follow-up period 33% of the patients had significant weight gain, irrespective of
group.28
The study by McIntyre et al. showed that the odds of excessive weight gain were significantly
higher for girls and adolescents aged 13 years or older compared with boys. The mean age
(standard deviation [SD]) at the onset of obesity was found to be 13.3 (3.7) years in this study.29
The study by Moreno et al. compared weight gain among young patients with bipolar disorder
(psychotic and non-psychotic) who were prescribed atypical antipsychotics. Results showed that
there was a gain of about 5.5 kg after the 3-month follow-up in the sample as a whole and no
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significant differences were found in weight gain among patients with psychotic or nonpsychotic disorders.30
Hyperglycemia: In a large cohort study, olanzapine was associated with the greatest increase in
glucose levels (3.14 mg/dL, 95% CI = 0.69 - 5.59, p-value < 0.05). Following olanzapine was
quetiapine, with moderately higher rates of hyperglycemia even though statistical significance
was not acheived.16 The study by Fraguas et al. did not show any statistically significant increase
in the glucose levels among the various atypical antipsychotics.28 This was similar to the results
of other longitudinal studies. Changes in fasting glucose did not reach statistical
significance.27,30-32
One study showed that girls were at an increased risk of developing diabetes mellitus (odds ratio
[OR] = 1.79, 95% CI = 1.28 – 2.50) compared with boys. Similarly adolescents over 13 years of
age and those who were exposed to multiple antipsychotics were at an increased risk of
developing diabetes mellitus compared with younger children. The mean (SD) at the onset for
incident type 2 diabetes mellitus was 13.8 (3.8) years.29
A possible mechanism could include antagonism of the serotonin 5-HT 1A/2A/2C receptors, which
results in the inhibition of insulin release, insulin resistance, or impaired glucose utilization. The
effects of atypical antipsychotics on alpha adrenergic receptors could also affect the pancreatic
beta cell function.33
Hyperlipidemia: A large cohort study showed that olanzapine and quetiapine had a statistically
significant baseline-to-endpoint change in total cholesterol, triglycerides, and non-HDL. The
levels of triglycerides with risperidone were raised significantly. Total cholesterol levels
increased by 15.58 mg/dL (95% CI = 6.88 - 24.28) and 9.05 mg/dL (95% CI = 0.41 - 17.69)
8

within the olanzapine and quetiapine groups, respectively. Triglycerides levels increased by
almost 37 mg/dL in the quetiapine group.16
A smaller cohort of 66 children also showed that total cholesterol levels had significantly
increased in the group of patients who had received olanzapine (p-value = 0.047) and quetiapine
(p-value = 0.016) but no significant changes were observed in the risperidone group.28
Interestingly, another cohort showed that the rate of dyslipidemia was higher in girls than among
boys (OR = 2.08, 95% CI = 1.41 - 3.03) and among those who received more than one
antipsychotic. The study also showed that the risk of patients with preexisting obesity and
hypertension developing dyslipidemia was almost 4.5 times greater if they had taken an
antipsychotic than if they were antipsychotic-naive.29 Another longitudinal study showed that
patients with bipolar disorder and other psychotic disorders had significant increase in
cholesterol levels at the end of three months while HDL and triglycerides did not change within
any group.30
One of the smaller studies in children with Tourette’s disorder showed similar results. Thirtythree of the total seventy-three children had developed lipid abnormalities over the course of the
study, 28 of the 33 had elevated low density lipoproteins (LDL) values, 8 had decreased HDL
values, and some others had elevated triglyceride values.31 In the study by Khan et al., fasting
lipid profiles were obtained for 72% of the 25 patients in the olanzapine group and for 75% of
the 24 patients receiving risperidone. In the olanzapine group, four of the patients had
triglyceride levels equal to or exceeding 110 mg/dL with one patient exceeding 250 mg/dL.
Similarly in the risperidone group, only one out of the 18 patients had triglyceride levels equal to
or exceeding 250 mg/dL.27
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Other Outcomes: Some of the studies also reported other outcomes that could be potentially
related to metabolic disturbances. Fraguas et al. showed that quetiapine was associated with a
statistically significant decrease in free thyroxine (FT4),28 and the systolic blood pressure among
patients taking olanzapine was higher than other antipsychotic groups.27,28 Moreno et al.
concluded that patients receiving second generation antipsychotics, especially higher doses, were
vulnerable to adverse health outcomes (i.e., decrease in FT4, increase in thyroid stimulating
hormone [TSH]).30
C. Risk of Metabolic Adverse Effects between Atypical Agents
Adult studies
A study was conducted by Lambert et al. to evaluate the association between antipsychotic
treatment and type 2 diabetes in adult patients with a diagnosis of schizophrenia. It was a
matched case-control study design conducted on California Medicaid beneficiaries. Patients with
type 2 diabetes were identified using diagnosis codes and receipt of an anti-diabetic medication.
Their results showed that the odds of developing type 2 diabetes were significantly higher in
patients treated with olanzapine than in patients treated with risperidone. The study concluded
that certain atypical antipsychotics (i.e., olanzapine and clozapine) are associated with
significantly increased risk of developing new onset diabetes.34
Another similar study by Lambert et al. looked at the association between antipsychotic
treatment and hyperlipidemia in patients with schizophrenia. The study concluded that the risk of
developing hyperlipidemia was higher among olanzapine users compared to other atypical
antipsychotics.35 The study reported that patients who had developed hyperlipidemia were more
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likely to have been exposed to olanzapine (OR = 1.20, 95% CI = 1.08-1.33). Exposure to
risperidone and quetiapine were not significantly associated with developing hyperlipidemia.35
Pediatric Studies
Table 2.1 shows the studies that have compared some of the atypical antipsychotics and their
propensity to cause metabolic adverse effects in children and adolescents. Except for one study
there were no significant changes in the blood glucose levels. Correll et al. reported that
olanzapine users did have a significant increase in their blood glucose levels.16
All the studies showed that olanzapine users had the highest weight gain when compared with
other antipsychotics. Quetiapine and risperidone users did have some weight gain. Since obesity
and weight gain are predictors for insulin resistance and glucose insensitivity, olanzapine users
may be pre-disposed to developing diabetes mellitus.
All the studies showed that children and adolescents using olanzapine had the highest increase in
triglycerides and total cholesterol levels in comparison with other psychotics. None of the studies
showed risperidone to have any significant effect on lipid levels.
The studies seem to indicate that olanzapine users have the highest risk of developing metabolic
adverse effects (e.g., hyperlipidemia and hyperglycemia).

11

Table 2.1: Review of studies
Reference
(year)

Correll et al.
(2009)16

Fraguas et
al. (2008)28

Khan et al.
(2009)27

Sikich et al.
(2008)32

Drugs Studied
A= Aripiprazole
O= Olanzapine
Q= Quetiapine
R= Risperidone

Glucose

Lipids
O: significant increase in
triglycerides, LDL and
total cholesterol

O: significant
increase by 3.14
mg/dL

O (8.5 kg) > Q (6.1 kg) > R
(5.3 kg)

R,Q: significant increase
in triglyceride

R= Risperidone
O= Olanzapine
Q= Quetiapine

No significant
increase

O= Olanzapine
R= Risperidone

No significant
changes in fasting
glucose

O: 4 patients with
elevated triglycerides

No significant
changes in glucose
profile

O: significant increase in
total cholesterol (19.9
mg/dL) and LDL (14.7
mg/dL)

O= Olanzapine
R= Risperidone

Weight Gain

O: 10 mg/dL increase in
total cholesterol

O (11 kg) > R (5 kg) > Q
(2.5 kg).
O: BMI increase by1.7
kg/m2
R: BM increase by 1.3
kg/m2
O: significant increase in
weight (6.1 kg)
R: increase of 3.6 kg

D. Type 2 Diabetes Mellitus in Children and Adolescents
Type 2 diabetes is characterized by insulin resistance and a decrease in insulin secretion. In
children, it may lead to the early onset of cardiovascular disease, retinopathy, nephropathy, and
neuropathy if uncontrolled.36 Other chronic complications include end-stage renal disease and
limb amputations. Because of these complications there is early morbidity and mortality among
diabetic patients.37 Type 2 diabetes is associated with other insulin resistant features (e.g.,
hyperlipidemia, hypertension and non-alcoholic fatty liver disease).38 In youth, the mean age of
onset is usually around 13.5 years and there is a greater prevalence among patients with nonwhite European descent.39
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Diagnostic criteria for type 2 diabetes in children and adolescents (any one of the three):39
1) A fasting plasma glucose ≥ 126 mg/dL
2) The post challenge plasma glucose is > 200 mg/dL
3) Symptoms (polyuria, polydypsia, blurring of vision, and weight loss) of diabetes and a
casual plasma glucose ≥ 200 mg/dL
The treatment of type 2 diabetes in children and adolescents is multifaceted. Non-pharmacologic
therapy (e.g., diet, exercise, and lifestyle modifications) is encouraged before pharmacologic
therapy is initiated. The first-line of therapy is metformin. It has similar HbA1c reducing
properties to sulfonylureas with minimal risk of hypoglycemia. Metformin can also help with
decreasing weight. Metformin is approved for pediatric use and other treatment options should
be initiated only after failure of monotherapy with metformin.39
E. Hyperlipidemia in Children and Adolescents
Cardiovascular disease is one of the leading causes of death in the United States. A clinical
report by Daniels et al. reports that even though the clinical burden of CVD occurs in adulthood,
the process of atherosclerotic CVD starts earlier on in life during childhood years.40 A clinical
trial found that 15.6% of girls and 11.1% of boys had total cholesterol concentrations greater
than 200 mg/dL.41
Ford et al. reported that only 0.8% of US teens had a LDL cholesterol level above the
recommended threshold level (>190 mg/dL or > 160 mg/dL with risk factors) requiring
pharmacotherapy. On the other hand, the study also reported that elevated cholesterol levels were
found to affect 9-10% of US teens.42
13

According to the latest National Cholesterol Education Program (NCEP) guidelines, the
following cut offs should be used to diagnose abnormal cholesterol concentrations in children
and adolescents: 43
1) Total cholesterol < 170 mg/dL and LDL < 110 mg/dL is acceptable
2) Total cholesterol 170-199 mg/dL and LDL 110-129 mg/dL is borderline
3) Total cholesterol ≥ 200 mg/dL and LDL ≥ 130 mg/dL is elevated
The NCEP does not recommend routine lipid screening for children 2-8 years of age and
adolescents 12-16 years of age unless they have diabetes, hypertension, increased BMI (≥ 95th
percentile for children and ≥ 85 th percentile for adolescents), history of smoking, a strong family
history of CVD, or a parent with total cholesterol greater than or equal to 240 mg/dL.43 For
children 9-11 years of age NCEP does recommend universal screening with a fasting lipid
panel.43
According to the guidelines, hyperlipidemia should be initially treated using non-pharmacologic
therapy (i.e., healthy lifestyle, dietary modifications). Dietary changes which focus on reducing
calorie intake from total and saturated fat are recommended (except for children younger than 2
years). Pharmacologic therapy is reserved only for children greater than or equal to 10 years old
with a LDL ≥ 190 mg/dL with no other risk factors, or ≥ 160 mg/dL with risk factors. Children
younger than 10 years should not receive pharmacologic therapy unless they have severe primary
hyperlipidemia or have a dramatic elevation in LDL ≥ 400 mg/dL or triglycerides ≥ 500 mg/dL.
If pharmacologic therapy is warranted, statin therapy should be considered.43 Statin therapies
have been shown to be safe and effective in children.44 The lowest available dose should be given
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once daily and children taking statins should have routine monitoring for adverse effects related
to muscle toxicity.43
F. Gaps in Literature
It is known that atypical antipsychotics can cause metabolic adverse effects in adults45 and a
study by Draeger et al. has reported the prevalence of anti-diabetic and antilipidemic medication
use among antipsychotic users in an adult population.46 Studies in the pediatric population have
shown that atypical antipsychotics have the propensity to cause metabolic adverse effects (e.g.,
weight gain, dyslipidemia and insulin resistance).16,27,28,32
No study has looked directly at the prevalence of anti-diabetic and antilipidemic medication use
among children and adolescents exposed to atypical antipsychotics. There is knowledge that
atypical antipsychotics can cause type 2 diabetes and hyperlipidemia but there is no information
about how many of these children are prescribed medications for these metabolic conditions.
Additionally, there are not studies that report the odds of receiving an anti-diabetic or
antilipidemic medication among the various atypical antipsychotic agents. This information
could help clinicians make informed decisions about which of the atypical antipsychotics is the
safest to prescribe.

15

Chapter 3: Methodology
A. Study Design and Data Source
This was a cross-sectional study using the Virginia Medicaid pharmacy claims data. The dataset
was obtained from the Department of Medical Assistance Services (DMAS), the agency that
administers Medicaid and CHIP (Children’s Health Insurance Program). Medicaid is the health
program that is targeted to help families with low income and people with certain disabilities.
For the purpose of this study, Medicaid was an ideal source of data because medication
information on children and adolescents could be obtained. All patient identifiers were removed
by DMAS to protect the privacy of the patient. Each subject was assigned a unique identifier
number by DMAS that was used to link the subject across files.
The study was approved by the Virginia Commonwealth University Institutional Review Board,
Office of Research Subjects Protection in February 2012.
B. Study Population
Virginia Medicaid beneficiaries were included in the study if they met the following inclusion
criteria:
(i) Subjects were between 2 and 17 years of age.
(ii) Subjects were continuously enrolled in the Medicaid system (Fee-For-Service and Managed
Care) from July 31, 2010 to August 1, 2011.
(iii) Only subjects with at least two paid prescription claims for the atypical antipsychotics
aripiprazole, quetiapine, olanzapine, risperidone, or ziprasidone were included to be in the
16

exposed group. The newer antipsychotic agents (i.e., lurasidone, paliperidone, iloperidone,
asenapine) were not included in the study as substantial use of these atypical antipsychotic agents
in the pediatric population had not been reported.
Subjects were excluded if they met any of the following criteria:
(i) They had juvenile diabetes identified using ICD-9-CM code 250.x1 or 250.x3.
(ii) They had paid pharmacy claims for a typical antipsychotic (e.g., haloperidol, thiothixene,
chlorpromazine, fluphenazine, and perphenazine).
(iii) They had paid claims for more than one atypical antipsychotic during the study period.
Subjects using more than one antipsychotic during the study period were excluded so that the
prevalence of the outcome could be attributed to the particular antipsychotic agent being studied.
C. Data Collection
After excluding subjects with ICD-9-CM codes for juvenile diabetes and those who had
pharmacy claims for typical antipsychotics, two data files were obtained from DMAS. The
exposed file included all the subjects who had paid pharmacy claims for atypical antipsychotics
during the study period. The file also included all other paid pharmacy claims the subjects had
during the year. The unexposed file included all subjects who had any pharmacy claims during
the study period but were not included in the first file.
Variables: Both files contained the following variables:
- Unique patient identifier: Each subject was assigned a unique 7-digit number.
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- Drug name and strength: Each claim was accompanied by the name of the drug and the
strength. Each drug was identified using the Generic Code Number (GCN) which groups drugs
with the same ingredients, strength, dosage form, and route of administration.
- Age: Age of the subjects was provided as a continuous variable measured in years. Categorical
variables for age were created. Subjects were divided into three categories: 2-4 years, 5-11 years,
and 12-17 years of age. The categories were based on the age categorization used by the Centers
for Disease Control and Prevention (CDC) which approximates pre-schoolers, middle childhood,
and teenagers.47
- Sex: Sex of the subjects was provided and treated as the categorical variables males and
females.
- Race: This categorical variable included White, African-American, American Indian,
Oriental/Asian, Hispanic, Native Hawaiian, Asian and White, African-American and White,
Unknown, Asian and African-American, and Other. The classes were collapsed into White,
African-American, and Others because of the smaller number of subjects among the other
groups.
D. Specific Aim I
Identification of Groups
Unexposed group: From the unexposed file given by DMAS, only subjects who were
continuously enrolled in Medicaid during the study period were included. These subjects
composed the unexposed group. The demographic variables age, sex, and race were reported for
the unexposed subjects.
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Exposed group: From the exposed file, only subjects who were continuously enrolled during the
study period and had at least two paid prescription claims for atypical antipsychotics were
included. All subjects who had prescription claims for more than one atypical antipsychotic were
excluded from this group. The remaining subjects comprised the exposed group. The
demographic variables age, sex, and race were reported for all exposed subjects.
Specific Aim IA: To determine and compare the prevalence of anti-diabetic medication use
in children and adolescents treated with atypical antipsychotics to those not treated with
atypical antipsychotics.
Outcome: In the unexposed and exposed groups, subjects using anti-diabetic medications were
identified from the pharmacy claims data using the GCN. The anti-diabetic agents included
insulin, glimepiride, glyburide, glipizide, metformin, glipizide/metformin, glyburide/metformin,
pioglitazone, pioglitazone/metformin, rosiglitazone, sitagliptin, acarbose, exenatide, and
liraglutide. Subjects who had a prescription claim for an anti-diabetic medication were assigned
outcome = 1 and other subjects without a prescription claim were assigned outcome = 0 .
Demographic variables age, sex, and race were reported for all subjects in each group who had
an anti-diabetic pharmacy claim. The prevalence of use of anti-diabetic medications was then
computed in the unexposed and exposed groups:

Prevalence= Number of subjects with claims for anti-diabetic medication in unexposed group
Total number of subjects in unexposed group

Prevalence= Number of subjects with claims for anti-diabetic medication in exposed group
Total number of subjects in exposed group
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Specific Aim IB: To determine and compare the prevalence of antilipidemic medication use
in children and adolescents treated with atypical antipsychotics to those not treated with
atypical antipsychotics.
Outcome: In the unexposed and exposed groups, subjects using antilipidemic medications were
identified from the pharmacy claims data using the GCN. The antilipidemic agents included
atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, cholestyramine, colestipol, niacin,
ezetimibe, fenofibrate, and gemfibrozil. Subjects who had a prescription claim for an
antilipidemic medication were assigned outcome = 1 and subjects without a prescription claim
for an antilipidemic medication were assigned outcome = 0. Demographic variables age, sex, and
race were reported for all subjects in each group who had an antilipidemic pharmacy claim. The
prevalence of use of antilipidemic medications was then computed in the unexposed and exposed
groups:

Prevalence= Number of subjects with claims for antilipidemic medication in unexposed group
Total number of subjects in unexposed group

Prevalence= Number of subjects with claims for antilipidemic medication in exposed group
Total number of subjects in exposed group
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E. Specific Aim II
Identification of Subgroups
Subjects who were identified as the exposed group in Specific Aim I were further classified into
five subgroups based on the atypical antipsychotic agent they received. The subgroups were
aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone users. The medications were
identified using the GCN. The demographics of the subjects receiving each atypical
antipsychotic subgroup were reported.
Specific Aim IIA: To examine the relationship between the use of individual atypical
antipsychotic agents and use of anti-diabetic medication in children and adolescents.
Outcome: Within the five antipsychotic subgroups, subjects using anti-diabetic medications were
identified from the pharmacy claims data. Subjects who had a prescription claim for an antidiabetic medication were assigned outcome = 1 and subjects without an anti-diabetic pharmacy
claim were assigned outcome = 0. The prevalence of use of anti-diabetic medications within each
atypical antipsychotic subgroup was computed:

Prevalence= Number of subjects with prescription claims for anti-diabetic medication
Total number of subjects using atypical antipsychotic X
X = aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone
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Specific Aim IIB: To examine the relationship between the use of individual atypical
antipsychotic agents and use of antilipidemic medication in children and adolescents.
Outcome: Within the five subgroups, subjects using antilipidemic medications were identified
from the pharmacy claims data. Subjects who had a prescription claim for an antilipidemic
medication were assigned outcome = 1 and subjects without an antilipidemic medication
pharmacy claim were assigned outcome = 0. The prevalence of use of antilipidemic agents by
subjects within each atypical antipsychotic subgroup was computed:

Prevalence= Number of subjects with prescription claims for antilipidemic medication
Total number of subjects using atypical antipsychotic X
X = aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone

F. Statistical Analyses
Descriptive statistics were used to summarize the demographic variables age, sex, and race.
Categorical data was described using percents and counts. Normal continuous data were
described using mean and standard deviation. Chi-square test of homogeneity was performed to
test for differences between age, sex, and race between the exposed and the unexposed groups.
Fisher’s exact test was used when there was inadequate cell size. The prevalence of outcomes
between unexposed and exposed groups was compared using Chi-square test of independence.
For the second specific aim, the number and percentage of subjects using each of the atypical
antipsychotics was reported.
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Logistic regression analyses were used to test the following:
Specific Aim IA: The relationship between exposure to atypical antipsychotics (Yes = exposed
group, No = unexposed group) and outcome (1 = anti-diabetic claim, 0 = no anti-diabetic claim).
Specific Aim IB: The relationship between exposure to atypical antipsychotics (Yes = exposed
group, No = unexposed group) and outcome (1 = antilipidemic claim, 0 = no antilipidemic
claim).
Specific Aim IIA: The relationship between exposure to individual atypical antipsychotic agent
(aripiprazole = 1, olanzapine = 2, quetiapine = 3, risperidone = 4, ziprasidone = 5) and outcome
(1 = anti-diabetic claim, 0 = no anti-diabetic claim).
Specific Aim IIB: The relationship between exposure to individual atypical antipsychotic agent
(aripiprazole = 1, olanzapine = 2, quetiapine = 3, risperidone = 4, ziprasidone = 5) and outcome
(1 = antilipidemic claim, 0 = no antilipidemic claim).
In the first specific aim, the unexposed group was used as the reference. For the second specific
aim, olanzapine was used as the reference. Since olanzapine had the highest propensity to cause
weight gain, dyslipidemia and glucose imbalance, it was chosen as the reference.16,

27, 30, 32

Logistic regression analyses were performed. Logistic regression analyses, controlled for age,
sex, and/or race, were also performed if the variables were found to have a significant
relationship with the outcome individually. The unadjusted and adjusted OR and 95% confidence
intervals were reported for all logistic regression analyses. For the adjusted OR, 2-4 years, male,
and White were used as the reference groups for age, sex, and race respectively. All tests were
performed at a significance level of 0.05, and SAS 9.3 statistical package was used for all
analyses.
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Chapter 4: RESULTS
A. Comparison of Subjects Exposed and Unexposed to Atypical Antipsychotics
DMAS provided two files after excluding subjects with a diagnosis of juvenile diabetes and
subjects with pharmacy claims for typical antipsychotics. One file was for the unexposed group
and the other for the exposed group. The unexposed file contained information on 2,502,643
pharmacy claims. After including only those subjects who were continuously enrolled in the
Virginia Medicaid system during the study period, a total of 299,593 unique subjects with
2,286,629 claims were identified in the unexposed group.
The second file had information on the subjects who were exposed to atypical antipsychotics. It
contained information on 438,124 pharmacy claims. As shown in Figure 4.1, 244,283 claims
remained after including only subjects with one year of continuous enrollment. After including
only those subjects who had at least 2 paid pharmacy claims per atypical antipsychotic, 53,236
claims remained. A total of 4,922 unique subjects were identified in the exposed group after
excluding for subjects receiving more than one atypical antipsychotic.
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Figure 4.1: Flow of claims after application of inclusion/exclusion criteria
Total number of claims after excluding for juvenile diabetes and claims for typical antipsychotics
438,124

Total number of claims after including only subjects with one year of continuous enrollment
244,183

Total number of claims after inlcuding only subjects with at least 2 paid claims for the atypical
antipsychotic of interest
53,236

Total number of patients after excluding patients with polypharmacy of atypical antipsychotics
4,922

(i) Baseline Characteristics of the Study Groups
Unexposed group: Table 4.1 illustrates the baseline demographic characteristics of the subjects
by exposure to atypical antipsychotics. The mean age (SD) of the total sample of unexposed
children was 8.23 (4.70) years with the highest percentage of children (43.34%) falling within
the category of 5- to 11-year-olds. Approximately 38% of the subjects were White and AfricanAmerican each and there was an equal distribution of males versus females.
Exposed group: Baseline characteristics of the subjects in the exposed group are shown in Table
4.1. The mean age of the subjects was 11.77 (3.65) years and almost 55% of the subjects were
between 12 and 17 years of age. More than two-thirds of the subjects were male and the majority
was White.
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The unexposed and exposed groups were significantly different in their baseline demographics
(Table 4.1). Therefore, age, sex, and race was controlled for in the logistic regression analyses.
Table 4.1: Baseline demographic characteristics of study subjects
Unexposed Group

Exposed Group

n (%)

n (%)

(N=299,593)

(N=4,922)

86,362 (28.83)

113 (2.3)

5-11 years

129,838 (43.34)

2,088 (42.42)

12-17 years

83,393 (27.84)

2,721 (55.28)

Mean (SD)

8.23 (4.70)

11.77 (3.65)

Males

150,059 (50.09)

3,367 (68.41)

<0.0001

Race: White

115,011 (38.39)

3,261 (66.25)

<0.0001

African-American

113,671 (37.94)

1,187 (24.12)

Others

70,911 (23.67)

474 (9.63)

Characteristic

Age: 2-4 years

Sex:

p-value

<0.0001

(ii) Prevalence of Anti-diabetic Medication Use
In the unexposed group, 957 of 299,593 subjects had paid claims for an anti-diabetic medication
during the study period. In the exposed group, 69 of 4,922 subjects had paid claims for an antidiabetic medication. The prevalence of anti-diabetic medication claims was 0.32% among
children and adolescents who were not exposed to antipsychotics and 1.40% in those exposed to
atypical antipsychotics. The prevalence of anti-diabetic medication use was significantly higher
among the subjects exposed to atypical antipsychotics compared with those who were not
exposed (χ2 = 168.96, df = 1, p-value < 0.0001). Demographics of subjects on anti-diabetic
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medications are shown in Table 4.2. Because of the small cell sizes, Fisher’s exact test was
performed. Sex and race were found to be significantly different between the two groups. There
were significantly more males in the exposed group who had claims for anti-diabetic
medications. There was no significant difference in the ages between the groups (p-value =
0.3667). Of the subjects with claims for antidiabetic drugs, 92.75% in the exposed and 83.70% in
the unexposed group had claims for metformin.
Table 4.2: Demographics of subjects with claims for anti-diabetic medications
Anti-diabetic claims
Characteristic

p-value

Unexposed
Group
n (%)
(N=957)
4 (0.42)

Exposed
Group
n (%)
(N=69)
1 (1.45)

5-11 years

175 (18.29)

13 (18.84)

12-17 years

778 (81.30)

55 (79.71)

Mean (SD)

13.82 (2.67)

13.86 (2.92)

Sex: Males

272 (28.42)

30 (43.48)

0.0131

Race: White

445 (46.50)

49 (71.01)

<0.0001

African-American

399 (41.69)

18 (26.09)

Others

113 (11.81)

2 (2.90)

Age: 2-4 years
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0.3667

Logistic regression analyses: In the regression analysis, exposure to an atypical antipsychotic
was found to be an important predictor to whether a subject received an anti-diabetic medication
(χ2 = 141.08, df = 1, p-value < 0.0001). The odds of having a claim for anti-diabetic medication
for children and adolescents exposed to an atypical antipsychotic agent were 4.44 (95% CI =
3.47 - 5.68) times higher than in children and adolescents not exposed to these agents. Age (χ2 =
679.04, df = 2, p-value < 0.0001), sex (χ2 = 169.29, df = 1, p-value < 0.0001), and race (χ2 =
85.32, df = 2, p-value < 0.0001) were found to have a significant relationship with receiving an
anti-diabetic medication. Table 4.3 summarizes the results of the unadjusted and adjusted logistic
regression analyses. After controlling for age, sex, and race the odds of having a claim for antidiabetic medication for children and adolescents exposed to an atypical antipsychotic agent were
2.76 (95% CI = 2.15 - 3.55, p-value < 0.0001) times higher than children and adolescents not
exposed to antipsychotics. Children between 5 and 17 years had higher odds of having antidiabetic medications compared with 2- to 4-year-olds. Female children were at higher odds of
being prescribed an anti-diabetic medication. White children had higher odds of anti-diabetic
medication use compared with African American children or those of other race.
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Table 4.3: Regression analyses for prevalence of anti-diabetic medications
Adjusted Regression Model
Unadjusted Regression Model
controlling for Age, Sex, and Race
95% CI

95% CI

OR

OR
Lower

Upper

Lower

Upper

2.15

3.55

Exposure
Unexposed

1 (reference)

Exposed

4.44

Age

N/A

1 (reference)
3.47

5.68

2.76

2-4 years

1 (reference)

5-11 years

23.23

9.56

56.47

12-17 years

146.09

60.62

352.05

2.04

2.67

Sex

N/A

Male

1 (reference)

Female

2.34

Race

N/A

White

1 (reference)

African-American

0.91

0.79

1.03

Others

0.61

0.50

0.75

(iii) Prevalence of Antilipidemic Medication Use
In the unexposed group, 261 of the 299,593 subjects had paid claims for an antilipidemic
medication during the year. Within the exposed group, 17 of the 4,922 subjects had paid claims
for an antilipidemic medication. The prevalence of antilipidemic medication use among children
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and adolescents who were not exposed to antipsychotics was 0.09% which was significantly
lower than the 0.35% prevalence of antilipidemic medication use in those exposed to atypical
antipsychotics (χ2 = 35.41, df = 1, p-value < 0.0001). Demographics of subjects on antilipidemic
medication use are listed in Table 4.4. Fisher’s exact test showed that sex and race were
significantly different between the two groups. In the exposed group, significantly more males
had claims for antilipidemic medications (p-value = 0.0416). There was no significant difference
in the ages between the groups (p-value = 0.2909). A total of 64.71% of the subjects in the
exposed and 55.17% subjects in the unexposed group had claims for statins.
Table 4.4: Demographics of subjects with claims for antilipidemic medications
Antilipidemic claims
Characteristic

Unexposed
Group
n (%)
(N=261)

Exposed
Group
n (%)
(N=17)

p-value

37 (14.18)

0

0.2909*

5-11 years

58 (22.22)

4 (23.53)

12-17 years

166 (63.60)

13 (76.47)

Mean (SD)

11.82 (4.93)

13.94 (3.75)

Sex: Males

146 (55.94)

14 (82.36)

0.0416

Race: White

142 (54.41)

14 (82.35)

0.0326

African-American

61 (23.37)

3 (17.65)

Others

58 (22.22)

0

Age: 2-4 years

*Non-significant
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Logistic regression analyses: In the regression analysis exposure to an atypical antipsychotic was
found to be an important predictor to whether a subject received an antilipidemic medication
(χ2 = 30.30, df = 1, p-value < 0.0001). The odds of having a claim for an antilipidemic
medication for children and adolescents exposed to the atypical antipsychotic agent were 3.97
(95% CI = 2.43 - 6.50) times higher than children and adolescents not exposed to antipsychotics.
Age (χ2 = 148.01, df = 2, p-value < 0.0001), sex (χ2 = 5.68, df = 1, p-value < 0.0171) and race
(χ2=36.24, df = 2, p-value < 0.0001) were found to have a significant association with whether
the subjects received an antilipidemic medication. Table 4.5 shows the results of the adjusted and
unadjusted logistic regression analyses. When controlled for age, sex, and race the odds of
having a claim for an antilipidemic medication for children and adolescents exposed to an
atypical antipsychotic agent were 2.12 (95% CI = 1.34 - 3.64, p-value = 0.0018) higher than
children and adolescents not exposed to these agents. Subjects 12 to 17 years of age were found
to have higher odds than 2- to 4-year-olds to receive antilipidemic medications. Unlike the
results with anti-diabetic medications, females were found to have lower odds than males to
receive an antilipidemic medication. White children had higher odds than African-American
children of having antilipidemic medication claims.
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Table 4.5: Regression analyses for prevalence of antilipidemic medications
Adjusted Regression Model
controlling for Age, Sex, and
Race

Unadjusted Regression Model

95% CI

95% CI

OR

OR
Lower

Upper

Lower

Upper

1.34

3.64

Exposure
Unexposed

1 (reference)

Exposed

3.97

Age

N/A

1 (reference)
2.43

6.50

2.21

2-4 years

1 (reference)

5-11 years

1.07*

0.71

1.61

12-17 years

4.76

3.32

6.82

0.57

0.93

Sex

N/A

Male

1 (reference)

Female

0.73

Race

N/A

White

1 (reference)

African-American

0.44

0.33

0.59

Others

0.82*

0.60

1.11

*Non-significant
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B. Comparison of Subjects Exposed to Atypical Antipsychotics by Drug
(i) Demographics of Subjects Using Select Atypical Antipsychotic Agent
Figure 4.2 shows the prevalence of subjects on each atypical antipsychotic agent during the study
period. Among subjects who were exposed to any one of the five atypical antipsychotics
(n=4,922), the largest number of the subjects had claims for risperidone while the fewest had
claims for olanzapine. The demographics based on atypical antipsychotic use are found in Table
4.6. Subjects having claims for olanzapine, quetiapine, and ziprasidone had a mean age of 13
years while risperidone users were the youngest. Among each of the atypical antipsychotic users,
there were more male than female users.
Figure 4.2: Percentage of subjects using each atypical antipsychotic agent

Risperidone

48.76%

Aripiprazole

27.00%

Quetiapine

Ziprasidone

Olanzapine

18.45%

3.21%

2.58%
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Table 4.6: Demographics of subjects using each atypical antipsychotic agent (n=4,992)
Age (years)

Sex
Drug

Aripiprazole

Olanzapine

Quetiapine

Risperidone

Ziprasidone

n

Males

Mean

(%)

(SD)

843

12.46

(63.43)

(3.35)

107

13.02

(84.25)

(3.29)

529

13.32

1329

127

908
(58.26)

(3.12)

1793

10.63

(74.71)

(3.67)

95

13.26

(60.13)

(3.08)

2400

158

Range
2-4 (%)

5-11 (%)

12-17 (%)

3-17

13 (0.98)

489 (36.79)

827 (62.23)

5-17

0

43 (33.86)

84 (66.14)

4-17

3 (0.33)

230 (25.33)

675 (74.34)

2-17

97 (4.04)

1286 (53.58)

1017 (42.38)

5-17

0

40 (25.32)

118 (74.68)

(ii) Prevalence of Anti-diabetic Medication Use
The prevalences of anti-diabetic medication use among the antipsychotic subgroups were
computed and shown in Table 4.7. The highest prevalence of concomitant anti-diabetic
medication use was among ziprasidone users (8.23%). Among olanzapine users, which were
hypothesized to have highest prevalence of concomitant anti-diabetic medication use, only
3.15% had claims for anti-diabetic agents. Risperidone users had the lowest prevalence of
concomitant anti-diabetic claims (0.46%).
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Table 4.7: Prevalence of anti-diabetic medication and antilipidemic medication use by drug
Atypical Antipsychotic Agent

Anti-diabetic (%)

Antilipidemic (%)

Aripiprazole (N=1329)

2.18

0.53

Olanzapine (N=127)

3.15

0.79

Quetiapine (N=908)

1.32

0.22

Risperidone (N=2400)

0.46

0.21

Ziprasidone (N=158)

8.23

1.27

Logistic regression analyses: Table 4.8 shows the results of the adjusted and unadjusted logistic
regression analyses. The regression model showed that individual atypical antipsychotic agent
use was significantly associated with whether the subject received an anti-diabetic medication
(χ2 = 53.57, df = 4, p-value < 0.0001). Risperidone users were found to have 0.14 (95% CI = 0.04
- 0.45) times lower odds than olanzapine users to receive an anti-diabetic medication.
Ziprasidone users were found to have 2.76 (95% CI = 0.88 - 8.67) times higher odds than
olanzapine to receive an anti-diabetic medication but this was not significantly different from
olanzapine users (p-value = 0.0829). Since race was not found to be significantly associated with
whether the subjects received an anti-diabetic medication or not in the exposed group (χ2 = 3.19,
df = 2, p-value = 0.2033), only age (χ2 = 15.16, df = 2, p-value = 0.0005) and sex (χ2 = 18.45, df
= 1, p-value < 0.0001) were added to the regression model. After controlling for age and sex,
antipsychotic use by agent was significantly associated with receipt of anti-diabetic medication
claim (χ2 = 44.54, df = 4, p-value < 0.0001). Risperidone users had 0.15 (95% CI = 0.04 - 0.47)
times lesser odds of receiving an anti-diabetic medication compared with olanzapine users.
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Ziprasidone had the highest odds but it was not significantly different than olanzapine users (pvalue = 0.2158).
Table 4.8: Regression analyses of concomitant anti-diabetic medication use
Adjusted Regression Model
Unadjusted Regression Model
controlling for Age, and Sex
95% CI

95% CI

OR

OR
Lower

Upper

Lower

Upper

Atypical
Antipsychotic
Olanzapine

1 (reference)

1 (reference)

Aripiprazole

0.69*

0.24

1.98

0.56*

0.19

1.63

Quetiapine

0.41*

0.13

1.30

0.29

0.09

0.94

Risperidone

0.14

0.04

0.45

0.15

0.04

0.47

Ziprasidone

2.76*

0.88

8.67

2.08*

0.65

6.65

Age

N/A

2-4 years

1 (reference)

5-11 years

0.44*

0.06

3.47

12-17 years

1.01*

0.13

7.64

1.47

3.95

Sex

N/A

Male

1 (reference)

Female

2.41

* Non-significant
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(iii) Prevalence of Antilipidemic Medication Use
The prevalence of antilipidemic medication use among individual antipsychotic users is shown in
Table 4.7. Risperidone users had the lowest prevalence of antilipidemic medication use (0.21%)
which was similar to the prevalence of quetiapine (0.22%). Even though it was expected that
olanzapine users would have the highest prevalence of antilipidemic medication use, ziprasidone
users had the highest prevalence at 1.27%.
Logistic regression analyses: The logistic regression analysis was not able to show that there was
a significant difference in the prevalence of receiving an antilipidemic medication between the
different antipsychotic agents (χ2=6.49, df = 4, p-value < 0.1653). Since age, sex, and race were
not found to have a significant relationship with whether the subjects received an antilipidemic
medication or not, they were not added into the regression model. The model showed that
ziprasidone users had the highest odds of 1.61 (95% CI = 0.14 - 18.02), and risperidone and
quetiapine users had the lowest odds of 0.26 (95% CI = 0.03 - 2.27) and 0.28 (95% CI = 0.02 3.09), respectively, but none were significantly different from olanzapine users for antilipidemic
medication use.
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Chapter 5: DISCUSSION
A. Main Findings
The use of atypical antipsychotics has been correlated with weight gain, insulin resistance, and
lipid abnormalities in adult populations.45 Draeger et al. assessed the prevalence of anti-diabetic
and antilipidemic medication use among adult users of atypical antipsychotics, and reported that
aripiprazole users had slightly higher odds than other atypical antipsychotic users of receiving an
anti-diabetic or antilipidemic medication.46
Though similar studies on anti-diabetic and antilipidemic mediation use have not been done in
the pediatric population there is evidence that atypical antipsychotics cause substantial weight
gain, insulin resistance, and metabolic syndrome.15,16,20,26,48,49 Studies have shown that increased
weight gain and obesity during childhood are indicative of early development of metabolic
syndrome, type 2 diabetes, and cardiovascular disease during adulthood.17,19 There are clinical
guidelines describing how to address and treat children and adolescents who have type 2
diabetes39 or hyperlipidemia.40 This raised the question of whether children on atypical
antipsychotics who develop insulin resistance and lipid panel changes had to be started on antidiabetic and antilipidemic medications.
To the best of our knowledge, this is one of the few studies that has evaluated the prevalence of
diabetic medication use among children exposed to atypical antipsychotics20 and the only study
to evaluate the prevalence of antilipidemic medication use among children. The prevalence of
anti-diabetic medication use was significantly higher among children and adolescents with
claims for atypical antipsychotics than those children and adolescents who were not using
atypical antipsychotics. We found that about 1.40% of atypical antipsychotic users had anti38

diabetic medications compared with 0.32% among non-antipsychotic users. The use of antidiabetic medications among atypical antipsychotic users was more than four times the use of
anti-diabetic agents among children not using atypical antipsychotics. This is similar to the
results of the study by Andrade et al. which showed that the incidence of diabetes appeared to be
more than four times higher among children and adolescents using atypical antipsychotics
compared with those who were not.20 In this study, we also estimated the odds of receiving antidiabetic agents after controlling for demographic characteristics (i.e., age, sex, and race). We
found that exposure to antipsychotics was still an important predictor of receipt of anti-diabetic
prescriptions. Metformin was the most commonly prescribed anti-diabetic medication which is in
accordance with the International Society for Pediatric and Adolescent Diabetes (ISPAD)
guidelines on treating type 2 diabetes in children and adolescents.39
The prevalence of antilipidemic medication use was 0.35% among atypical antipsychotic users
and 0.09% among non-users. The use of antilipidemic medications among children prescribed
antipsychotics was almost four times higher than the prevalence of antilipidemic agents among
non-users. Even after adjusting for demographic factors, the odds remained higher for
antipsychotic users. According to the NCEP guidelines, pharmacotherapy should be reserved
only for those children above 10 years of age with LDL levels exceeding 190 mg/dL.43
Pharmacologic therapy should be reserved for children less than 8 years of age with a dramatic
elevation in cholesterol values (i.e., over 500 mg/dL). A study by Ford et al. showed that 0.8% of
teenagers in the United States had LDL values above the cut-off of 190 mg/dL thereby requiring
pharmacotherapy.42 This would imply that the true number of atypical antipsychotic users with
hyperlipidemia is higher than 0.35% because only a small fraction of these children would have
been started on a drug regimen.
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Though the prevalence rates are relatively small, the clinical impact is relevant. Our study
showed that 69 and 17 children out of the 4,922 subjects exposed to atypical antipsychotics were
prescribed anti-diabetic and antilipidemic medications, respectively. These numbers came from
only one Medicaid database during the period of one year, therefore the numbers at a national
level would be higher and could be a cause for concern. Studies have shown that children and
adolescents with abnormalities in their glucose or lipid levels are at higher risk to develop
hypertension and dyslipidemia as adults.39 Children and adolescents prescribed atypical
antipsychotics could be predisposed to develop diabetes, hyperlipidemia, and hypertension as
adults.
Most of the demographic results of this study are consistent with published trials. In previous
reports, the majority of the atypical antipsychotic users were males20, 28 and White28 which was
consistent with our results of 68% males and 66% White. The mean age of children receiving
atypical antipsychotics in our study was about 12 years which is less than the mean age of 15
years reported by Fraguas et al.28 This could reflect the fact that the Fraguas study was
conducted between 2001 and 2005, before aripiprazole, risperidone, quetiapine, and olanzapine
received FDA approval for pediatric use and the use of these agents might have been reserved for
older chlidren.
It was reported by McIntyre et al. that the odds of developing type 2 diabetes mellitus were
higher for girls and adolescents.29 The Agency for Healthcare and Research and Quality (AHRQ)
does state that women are at higher risk of developing diabetes and that weight gain is a risk
factor. Our study showed that females and adolescents had higher odds of receiving anti-diabetic
medications. A limitation in our findings is that metformin can also be used off-label to treat
polycystic ovarian syndrome (PCOS) in female children and adolescents50 and our study did not
40

exclude for subjects with PCOS. A study has shown that 5% of women develop PCOS and
require pharmacotherapy.51 In addition; metformin has been prescribed for the treatment and
prevention of atypical antipsychotic–induced weight gain and metabolic changes.52
The same study by Fraguas et al. reported that the odds of developing dyslipidemia were higher
for females and adolescents28 but our study showed that the odds of receiving antilipidemic
medications were significantly higher for males and adolescents. Larger studies using data from
multiple states are needed to obtain robust results.
Atypical antipsychotics are being used in children and adolescents to treat various neuropsychiatric disorders

(e.g., irritability associated with autism, tics, bipolar mania,

schizophrenia).14 Even though some of the atypical antipsychotics are approved for pediatric use
by the FDA, most are only approved for children as young as 10 years old. Risperidone is
indicated for the treatment of irritability associated with autistic disorder in children as young as
5 years old.53 Our study showed that atypical antipsychotics were being used in children as
young as 2 years old which indicates that these agents were being prescribed off-label in this
young pediatric population.
Our study showed that the most commonly prescribed atypical antipsychotic was risperidone
while the least commonly prescribed was olanzapine during the study period. A retrospective
study by Pathak et al. of a state’s Medicaid administrative claims data from 2001-2005 reported
that risperidone was the therapy initiated for most children while ziprasidone was the least
common therapy initiated in new users.54 A possible explanation for the high use of risperidone
could be that risperidone has been commercially available for a longer period of time and had
received its pediatric indication earlier than other atypical antipsychotics. The use of ziprasidone
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during the study by Pathak et al. was off-label. Over the years, the increasing use of ziprasidone
may be reflective of published literature supporting the use of ziprasidone over agents with a
higher propensity to cause metabolic effects (i.e., olanzapine).16,28 Our study has shown that the
use of olanzapine among children was less frequent than risperidone which may be secondary to
the number of studies reporting the harmful effects of olanzapine in children.26
A study by Seida et al. showed that there were no major differences among olanzapine,
risperidone, and quetiapine in insulin resistance.55 Another study by Correll et al. showed that
olanzapine, and quetiapine had higher propensity to cause increase glucose levels.16 In contrast, a
study by Cohen et al. reported that risperidone caused a greater glucose imbalance than
olanzapine.56 There has been varying evidence on the propensity of each drug to cause glucose
imbalance. Our study, which specifically looked at receipt of anti-diabetic medication, showed
that risperidone users had the lowest prevalence of anti-diabetic medication use. Children and
adolescents who were prescribed risperidone had lower odds than olanzapine users to receive an
anti-diabetic medication. Interestingly, our study showed that ziprasidone users had a higher
prevalence of anti-diabetic medication use than olanzapine users. However, the OR was not
found to be significantly different between olanzapine and ziprasidone users. The small sample
sizes in the ziprasidone and olanzapine groups are limitations; hence there may not have been
enough power to detect a significant difference. Ziprasidone use among children has not been
studied as extensively as the other antipsychotics. Most of the studies were very short term and
the longer studies had very limited sample sizes.26 Definitive conclusion regarding the metabolic
effects of ziprasidone in children cannot be made until more studies are published in this area.
Because of the cross-sectional nature of our study, it cannot be determined whether some of the
ziprasidone users were children who had previously used olanzapine and were switched
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secondary to metabolic adverse effects. Ziprasidone users in our trial were in a higher age
category compared with olanzapine users. Because of these limitations, conclusions regarding
ziprasidone cannot be made based on our data.
The studies by Correll et al. and Fraguas et al. have shown that olanzapine was associated with
the highest change in lipid levels among children and adolescents.16,28 Our study failed to
identify differences in the odds of receiving antilipidemic medications among the various
antipsychotic users. The prevalence was the highest among ziprasidone users, followed by
olanzapine users, and the lowest among risperidone users. However, the differences were not
statistically significant. The failure to show a statistical difference could be because of the small
number of children with antilipidemic mediation use, and hence there may not have been enough
power to reach statistical difference. It is interesting to note that with just 17 children having
antilipidemic prescriptions among antipsychotic users, a significance level of 0.1653 was
reached. It may be a worthwhile attempt to replicate this study in a larger setting with more
power.
This study adds to the findings of the trials that have been published. To the best of our
knowledge, this is the only study that has looked at antilipidemic medication use in children and
adolescents and one of the few studies that evaluated anti-diabetic medication use.20 There are
studies that have looked at adverse effects of antipsychotics or have addressed the development
of type 2 diabetes mellitus. Several studies have evaluated the development of hyperlipidemia in
children and adolescents on atypical antipsychotics,16 but none have reported actual antilipidemic
medication use in this population. Since there were differences in the demographics between the
groups, regression analyses controlling for these variables were done to see how they would
affect the nature of the relationship. We also computed the prevalence of anti-diabetic and
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antilipidemic medication use among a non-exposed group that was identified from the same
Medicaid database to use as a comparator group. This is the only study that has assessed the odds
of receiving anti-diabetic and antilipidemic medications among the various individual
antipsychotics. Clinicians can use the prevalence and the odds of receiving anti-diabetic
medication among atypical antipsychotic users to make informed decisions. The study has also
set the groundwork for more studies in this area, possibly in larger, multicenter settings.
B. Limitations
Firstly, this is a cross-sectional study; hence we cannot establish any causal relationship between
exposure to atypical antipsychotics and receipt of anti-diabetic or antilipidemic medications. This
is not a longitudinal study looking at the long term effects of antipsychotic use. We have tried to
address this limitation within the constraints of the study design by including only those subjects
who had at least two paid claims for any one antipsychotic.
Secondly, because of the nature of the study, antipsychotic use is a crude measure. We cannot
distinguish if subjects were switched from one antipsychotic before the study period. For
example, if a patient developed diabetes while using olanzapine then was switched to ziprasidone
and initiated on metformin, the anti-diabetic claim would have been included for this ziprasidone
user. Also, it cannot be assumed that because a prescription for a medication was dispensed, it
was consumed by the patient.
Thirdly, there were varying sample sizes between the antipsychotic users and a small number of
subjects with the outcomes of interest. Some of the sample sizes may have been too small to
reach statistical significance.
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A fourth limitation is potential confounders that were not controlled for. Factors such as physical
activity, diet, and family history could affect the risk of receiving anti-diabetic and antilipidemic
agents. A survey-based design would be more appropriate to capture such variables. We also did
not adjust for pre-existing diabetes or hyperlipidemia. Confounding by indication could also be a
potential limitation because metformin could have been used to treat other disorders (e.g.,
PCOS), or used to treat or prevent weight gain or metabolic effects of atypical antipsychotics and
not just diabetes.
Lastly, a major limitation is the limited generalizability of the study since this study used data
from only a single state Medicaid pharmacy claims database. The results cannot be generalized
to other pediatric populations, especially among those children not enrolled in Medicaid.
C. Future Directions
Further research should be done in this area to study the effects of all atypical antipsychotics.
There is a need to carry out similar studies in a larger setting, i.e., a multi-state Medicaid study.
This would ensure a larger sample and enough observations within each category to identify true
differences. Studies should also examine the newer antipsychotics (e.g., lurasidone, asenapine)
even though their use has not been significant among children and adolescents. Studies could
also incorporate variables such as diet, physical activity, polypharmacy of antipsychotics, and
concurrent use of other psychotropic medications, and study their individual relationship with the
probability of receiving anti-diabetic or antilipidemic medications.
More longitudinal studies looking at long term effects of exposure to atypical antipsychotics in
children and adolescents are needed after excluding for pre-existing diabetes and hyperlipidemia.
The results of these studies could help clinicians with informed decision making.
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D. Conclusion
In summary, the prevalence of anti-diabetic and antilipidemic medication use among children
and adolescents using atypical antipsychotics (olanzapine, risperidone, quetiapine, aripiprazole,
and ziprasidone) was almost four times higher than the prevalence among children and
adolescents not treated with the atypical antipsychotics. Risperidone users had lower odds of
receiving anti-diabetic medication compared with olanzapine users. There were no significant
differences between the individual atypical antipsychotics and receipt of antilipidemic agents.
We also found that age, sex, and race were significant predictors of whether children on atypical
antipsychotics received anti-diabetic and antilipidemic medications.
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